Biotechnology

Tuesday Jan 03, 2023 - 1:06 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA application will request approval for Adimune to conduct the first-in-human…

Thursday Dec 29, 2022 - 1:20 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market

BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis, and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute…

Thursday Dec 29, 2022 - 11:17 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Shareholder Letter, Including Corporate Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic noted that 2022 was a “transformative” year for HeartBeam, highlighted by ongoing advancements in the company’s product launch timeline for the HeartBeam AIMIGo(TM) 12-Lead 3D…

Wednesday Dec 28, 2022 - 11:03 am

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) RoomMate(TM) Delivers Efficiency, Privacy for Alzheimer’s, Dementia and ADA Patients

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, recently signed a letter of intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). “RoomMate, one of MetAlert’s flagship products, is a wall-mounted alert system that delivers both efficiency and privacy. It detects and alerts caregivers about patient…

Thursday Dec 22, 2022 - 9:50 am

InvestorNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions, acted as sole bookrunner on an $8 million underwritten public offering for BiondVax Pharmaceuticals. BiondVax…

Tuesday Dec 20, 2022 - 2:11 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each…

Tuesday Dec 20, 2022 - 11:26 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Files Updated Life Sciences Presentation

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products.…

Tuesday Dec 20, 2022 - 11:04 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage –…

Friday Dec 16, 2022 - 3:24 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Game-Changing, Potentially Lifesaving GPS SmartSole in Canada

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, is a solution leader for consumers and patients with needs for remote monitoring. “MetAlert has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with…

Friday Dec 16, 2022 - 3:00 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

HeartBeam (NASDAQ: BEAT), a cardiac technology company, recently named a world-renowned interventional cardiologist with an impressive breadth of experience as its chief medical officer. “Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere… Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors.…

Friday Dec 16, 2022 - 10:44 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit…

Friday Dec 16, 2022 - 10:00 am

InvestorNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) to Contribute to Domestic Energy Security, Supply U308 to US Uranium Reserve

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium and rare earth elements (“REE”), today announced that it has been awarded a contract to sell $18.5 million of natural uranium concentrates (“U3O8”) to the U.S. government for the establishment of a strategic “Uranium Reserve.” The U.S. National Nuclear Security Administration (“NNSA”), an office within the U.S. Department of Energy (“DOE”), is…

Wednesday Dec 14, 2022 - 3:55 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

Nutriband (NASDAQ: NTRB, NTRBW) has announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The company’s trading is expected to commence on Upstream under ticker symbol NTRB at 10:00am ET on Jan. 5, 2023. “Building shareholder value and increasing our liquidity is always a high priority for…

Wednesday Dec 14, 2022 - 2:15 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to…

Tuesday Dec 13, 2022 - 3:22 pm

InvestorNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event

Keros (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical…

Tuesday Dec 13, 2022 - 2:46 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused…

Tuesday Dec 13, 2022 - 10:02 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial…

Monday Dec 12, 2022 - 12:18 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and…

Friday Dec 09, 2022 - 11:20 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured in ‘Stocks to Watch’ by Markets Herald

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The company was featured in a “Stocks to Watch” report published by Markets Herald, which offers current market trends and analysis across various sectors. “MetAlert (OTC: MLRT) took a significant step forward in the fourth quarter of 2022 by eliminating all toxic convertible notes from its…

Friday Dec 09, 2022 - 10:17 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $57.00/ADS. The publication reads, “On November 30, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the third quarter of 2022 and provided…

Thursday Dec 08, 2022 - 11:33 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age,…

Wednesday Dec 07, 2022 - 2:36 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured in Research Report

Ludlow Research has announced that it updated its research opinion on MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The update is based on MetAlert’s elimination of toxic debt, as well as the launch of new medical device products for cognitive markets. “Toxic debt, or variable convertible notes, are a form of debt, which sometimes…

Wednesday Dec 07, 2022 - 11:19 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Signs Agreement to Build Exclusive AIMIGo 12-Lead 3D VECG Device

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is partnering with medical device manufacturing company Evolve Manufacturing Technologies to build its credit-card-sized AIMIGo(TM) 3D vector electrocardiogram (“VECG”) recording device; the device is designed to provide a 12-lead ECG readout to detect heart attacks remotely. According to the announcement, HeartBeam…

Wednesday Dec 07, 2022 - 11:13 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry

India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022. The legislation establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development. “The study and development of cannabis for its potential therapeutic benefits…

Wednesday Dec 07, 2022 - 10:02 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel…

Tuesday Dec 06, 2022 - 12:28 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Engages IBN for Corporate Communications Expertise

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, today announced its selection of the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities. With over 20 years of experience and an extensive portfolio of 30+ patents, MetAlert is a leading provider of innovative technology solutions to consumers/patients afflicted with Alzheimer’s, dementia…

Tuesday Dec 06, 2022 - 10:29 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary…

Monday Dec 05, 2022 - 10:39 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment community direct access to ask their questions to Climaco on…

Friday Dec 02, 2022 - 1:19 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’

HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for…

Friday Dec 02, 2022 - 9:40 am

InvestorNewsBreaks — MetAlert Inc. (MLRT) Engages Veteran Firm as Financial Advisor to Assist with Growth Strategy, Corporate Development Initiatives

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, announced that Joseph Gunnar & Co. LLC will serve as the company’s financial advisor. According to the announcement, Joseph Gunnar will support the company as it communicates its growth strategy to the investment community; the firm will also provide advice on possible financing alternatives and acquisitions and will…

Friday Dec 02, 2022 - 9:35 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms

India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According to the announcement, the company has commenced the phase 2 study at two U.S. sites and plans to add between three to five additional sites in the United…

Thursday Dec 01, 2022 - 12:27 pm

InvestorNewsBreaks — MetAlert Inc. (MLRT) ‘Groundbreaking’ Tech for Senior Health Care Market Spotlighted in Recent Article

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, is featured in a recent Market Herald article for its proprietary technologies, including RoomMate(TM). The article, which is titled “One Company Is Set to Pioneer Technologies for the Senior Health Care Market,” reports on RoomMate, MetAlert’s groundbreaking 3D fall detection and monitoring device. The 3D infrared…

Thursday Dec 01, 2022 - 9:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up to 1,889,764 shares of common stock at a combined public…

Wednesday Nov 30, 2022 - 1:59 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the…

Tuesday Nov 29, 2022 - 3:28 pm

InvestorNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include…

Tuesday Nov 29, 2022 - 1:16 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a…

Tuesday Nov 29, 2022 - 11:47 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed…

Tuesday Nov 29, 2022 - 9:52 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted…

Wednesday Nov 23, 2022 - 2:55 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and…

Wednesday Nov 23, 2022 - 10:52 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions